Clinical Trial Update: Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia [Phase 1, Phase 2]

View source ↗

Summary

This open-label PK, PD, and DDI study evaluated dotinurad in combination with allopurinol in gout patients with hyperuricemia and has completed Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• Allopurinol (Allopurinol)
• Dotinurad (dotinurad)

Snippet

Sponsor: Urica Therapeutics Inc. | Conditions: Gout, Hyperuricemia | Phase 1, Phase 2 | Status: COMPLETED